Calidi Biotherapeutics (CLDI) Operating Income (2022 - 2025)
Calidi Biotherapeutics' quarterly Operating Income came in at -$4.5 million in Q4 2025, down 10.93% year-on-year from -$5.0 million in Q4 2024, and up 11.53% quarter-over-quarter from -$5.0 million in Q3 2025.
Calidi Biotherapeutics has reported Operating Income for 4 years, with the latest figure at -$4.5 million in Q4 2025.
- For the quarter ending Q4 2025, Operating Income fell 10.93% year-over-year to -$4.5 million; the trailing twelve-month figure through Dec 2025 stood at -$20.2 million (up 7.05% YoY), and the FY2025 full-year result was -$20.2 million, up 7.05% from the prior year.
- Operating Income for Q4 2025 stood at -$4.5 million, up from -$5.0 million in the prior quarter.
- The five-year high for Operating Income was -$361622.0 in Q2 2022, with the low at -$9.8 million in Q4 2023.
- Average Operating Income over 4 years is -$5.2 million, with a median of -$5.3 million recorded in 2023.
- Year-over-year, Operating Income plunged 1707.69% in 2023 and jumped 59.0% in 2024.
- Tracing CLDI's Operating Income over 4 years: stood at -$4.7 million in 2022, then plunged by 109.47% to -$9.8 million in 2023, then jumped by 59.0% to -$4.0 million in 2024, then dropped by 10.93% to -$4.5 million in 2025.
- The last three Operating Income figures came in at -$4.5 million (Q4 2025), -$5.0 million (Q3 2025), and -$5.7 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 642.90 Mn |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | -3.82 Mn |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 268.64 Mn |
| 10 | Calidi Biotherapeutics | - | - | - | -4.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -4.47 Mn |
| Sep 30, 2025 | -5.05 Mn |
| Jun 30, 2025 | -5.66 Mn |
| Mar 31, 2025 | -5.06 Mn |
| Dec 31, 2024 | -4.03 Mn |
| Sep 30, 2024 | -5.23 Mn |
| Jun 30, 2024 | -5.77 Mn |
| Mar 31, 2024 | -6.75 Mn |
| Dec 31, 2023 | -9.82 Mn |
| Sep 30, 2023 | -7.22 Mn |
| Jun 30, 2023 | -6.54 Mn |
| Mar 31, 2023 | -5.41 Mn |
| Dec 31, 2022 | -4.69 Mn |
| Sep 30, 2022 | -6.99 Mn |
| Jun 30, 2022 | -361,622.00 |
| Mar 31, 2022 | -528,858.00 |